<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157153</url>
  </required_header>
  <id_info>
    <org_study_id>C1702</org_study_id>
    <nct_id>NCT04157153</nct_id>
  </id_info>
  <brief_title>First in Men Study: BIOMAG-I</brief_title>
  <official_title>BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, first-in-man trial. Up to 115 subjects will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical follow-up visits will take place at 1, 6, and 12 months and annually thereafter&#xD;
      until 36 months post procedure.&#xD;
&#xD;
      All subjects will undergo an angiographic follow-up at 6- and 12-month follow up.&#xD;
&#xD;
      IVUS, (including IVUS-VH documentation) and OCT will be performed for all subjects at 6-month&#xD;
      and 12-month follow-up (if the safety of the subject allows it and as per the investigator's&#xD;
      decision).&#xD;
&#xD;
      Vasomotion will be assessed angiographically with Acetylcholine followed by Nitroglycerine at&#xD;
      12 months follow up in a subgroup of subjects, upon the investigators discretion and if&#xD;
      subject consents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In scaffold late lumen loss</measure>
    <time_frame>At 6 months after index procedure</time_frame>
    <description>Independent Core Lab Assessment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 36 monts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold</intervention_name>
    <description>Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt; 18 years and &lt; 80 years of age&#xD;
&#xD;
          2. Written subject informed consent available prior to PCI&#xD;
&#xD;
          3. Subject eligible for PCI&#xD;
&#xD;
          4. Subjects with a maximum of two single lesions in two separate coronary arteries which&#xD;
             have to be de novo lesions and can be covered with 1 device each&#xD;
&#xD;
          5. Reference vessel diameter between 2.5-4.2 mm by visual estimation, depending on the&#xD;
             scaffold size used&#xD;
&#xD;
          6. Target lesion length ≤ 28 mm by visual estimation, depending on the scaffold size used&#xD;
&#xD;
          7. Target lesion stenosis by visual estimation &gt; 50% - &lt; 100% and TIMI flow ≥1 (assisted&#xD;
             by e.g. QCA / IVUS /FFR).&#xD;
&#xD;
          8. Subjects with stable or unstable angina pectoris or documented silent ischemia or&#xD;
             hemodynamically stable NSTEMI patients without angiographic evidence of thrombus at&#xD;
             target lesion&#xD;
&#xD;
          9. Eligible for Dual Anti Platelet Therapy (DAPT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding females or females who intend to become pregnant during the&#xD;
             time of the study&#xD;
&#xD;
          2. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with&#xD;
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index&#xD;
             procedure.&#xD;
&#xD;
          3. Left main coronary artery disease&#xD;
&#xD;
          4. Three-vessels with coronary artery disease requiring treatment at time of procedure&#xD;
&#xD;
          5. Planned interventional treatment of any non-target vessel within 12-month&#xD;
             post-procedure&#xD;
&#xD;
          6. Subjects on dialysis&#xD;
&#xD;
          7. Planned intervention of the target vessel post index procedure&#xD;
&#xD;
          8. Ostial target lesion (within 5.0 mm of vessel origin)&#xD;
&#xD;
          9. Target lesion involves a side branch &gt;2.0 mm in diameter&#xD;
&#xD;
         10. Documented left ventricular ejection fraction (LVEF) ≤ 30% within the last 6 months&#xD;
&#xD;
         11. Heavily calcified lesion&#xD;
&#xD;
         12. Target lesion is located in or supplied by an arterial or venous bypass graft&#xD;
&#xD;
         13. Target lesion requiring treatment with a device other than the non-compliant&#xD;
             pre-dilatation balloon or scoring balloon prior to scaffold placement (including but&#xD;
             not limited to rotational atherectomy, etc.)&#xD;
&#xD;
         14. Unsuccessful pre-dilatation, defined as a residual stenosis rate more than 20%,&#xD;
             estimated by any method and/or angiographic complications (e.g. distal embolization,&#xD;
             side branch closure, extensive dissections)&#xD;
&#xD;
         15. Known allergies to: Acetylsalicylic Acid (ASA), P2Y12 inhibitors, Heparin, Contrast&#xD;
             medium, Sirolimus, or similar drugs; or the scaffold material&#xD;
&#xD;
         16. Subject is receiving an oral or intravenous immuno-suppressive therapy (e.g., inhaled&#xD;
             steroids are not excluded) or has a known life-limiting immunosuppressive or&#xD;
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus)&#xD;
             diabetes mellitus is not excluded)&#xD;
&#xD;
         17. A stenosis located proximal or distal to the target lesion that might require future&#xD;
             revascularization or an impede run off detected during diagnostic angiography&#xD;
&#xD;
         18. Life expectancy less than 1 year&#xD;
&#xD;
         19. Planned surgery or dental surgical procedure within 6 months after index procedure&#xD;
             unless DAPT will be maintained&#xD;
&#xD;
         20. In the investigators opinion, subject will not be able to comply with the follow-up&#xD;
             requirements&#xD;
&#xD;
         21. Subject is currently participating in another study with an investigational device or&#xD;
             an investigational drug and has not reached the primary endpoint yet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Haude, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheinland Klinikum Lukaskrankenhaus Neuss</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Sauter, PhD</last_name>
    <phone>+41448645575</phone>
    <phone_ext>5575</phone_ext>
    <email>stephanie.sauter@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souheila Moutiq, Msc</last_name>
    <phone>+41448645575</phone>
    <phone_ext>5625</phone_ext>
    <email>souheila.moutiq@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Toth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferdinande Bert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Bennett, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Toelg, PD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz-und Gefäßzentrum Oberallgäu-Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Torzewski, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Wiemer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Münich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Joner, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheinland Klinikum Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Haude, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene van der Schaaf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miedziowe Centrum Zdrowia SA</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Włodarczak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Göran Olivecrona, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Iglesias, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

